Wolfgang Briegel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wolfgang Briegel has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Martina Schimek
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Leopoldina Hospital, Schweinfurt, Germany
4 shared publications- Andreas Karwautz
Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria
3 shared publications - Christian Fleischhaker
Klinik für Psychiatrie, Psychotherapie und Psychosomatik im Kindes- und Jugendalter, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Freiburg im Breisgau, Deutschland
3 shared publications - Christoph U. Correll
Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA
3 shared publications Inge Kamp-Becker
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Marburg, Marburg, Germany
3 shared publications- Karin Egberts
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Mental Health, University Hospital of Wuerzburg, Wuerzburg, Germany
3 shared publications
Latest Publications
- 30 October 2026
- Published by Wiley in Counselling and Psychotherapy Research
- Vol. 26 (4)
Learning to Code Dyadic Parent–Child Interaction: An Exploratory Study
Objective: Diagnostic assessment through the Dyadic Parent–Child Interaction Coding System (DPICS) is inextricably linked to Parent–Child Interaction Therapy (PCIT), an evidence‐based parent management programme. However, there is a paucity of research on factors that may promote or hinder DPICS learning, including workshop format characteristics, trainee variables, and the quantity and complexity of verbalisations captured through DPICS coding. This study aims to bridge this gap. Methods: To do this, this study used an exploratory, quasi‐experimental design to identify workshop and trainee characteristics that influence effective learning of DPICS coding. Data for this study were collected across 14 cohorts of 40‐h PCIT basic training workshops including 82 participants. Results: The findings of this study suggest that the basic PCIT workshop format (one‐stage vs. two‐stage workshop), primary psychotherapeutic orientation, pre‐workshop DPICS coding experience, preparation time for DPICS coding before the workshop, attitude towards DPICS coding importance, DPICS coding confidence or time spent on DPICS homework during the workshop do not exert a significant influence on DPICS coding competency as assessed by the DPICS inter‐coder agreement (ICA). In contrast, fewer years of pre‐workshop clinical practice and native speaker status were statistically significantly associated with higher ICA. Conclusion: Implementing a systematic plan for DPICS training throughout the PCIT training process seems to be highly advisable, particularly for non‐native‐speaker trainees and trainees with extensive pre‐workshop clinical experience. To further elucidate the factors influencing PCIT training outcomes, multi‐centre studies with more participants are needed.
- 30 October 2026
- Published by Wiley in Counselling and Psychotherapy Research
- Vol. 26 (4)
Learning to Code Dyadic Parent–Child Interaction: An Exploratory Study
Objective: Diagnostic assessment through the Dyadic Parent–Child Interaction Coding System (DPICS) is inextricably linked to Parent–Child Interaction Therapy (PCIT), an evidence‐based parent management programme. However, there is a paucity of research on factors that may promote or hinder DPICS learning, including workshop format characteristics, trainee variables, and the quantity and complexity of verbalisations captured through DPICS coding. This study aims to bridge this gap. Methods: To do this, this study used an exploratory, quasi‐experimental design to identify workshop and trainee characteristics that influence effective learning of DPICS coding. Data for this study were collected across 14 cohorts of 40‐h PCIT basic training workshops including 82 participants. Results: The findings of this study suggest that the basic PCIT workshop format (one‐stage vs. two‐stage workshop), primary psychotherapeutic orientation, pre‐workshop DPICS coding experience, preparation time for DPICS coding before the workshop, attitude towards DPICS coding importance, DPICS coding confidence or time spent on DPICS homework during the workshop do not exert a significant influence on DPICS coding competency as assessed by the DPICS inter‐coder agreement (ICA). In contrast, fewer years of pre‐workshop clinical practice and native speaker status were statistically significantly associated with higher ICA. Conclusion: Implementing a systematic plan for DPICS training throughout the PCIT training process seems to be highly advisable, particularly for non‐native‐speaker trainees and trainees with extensive pre‐workshop clinical experience. To further elucidate the factors influencing PCIT training outcomes, multi‐centre studies with more participants are needed.
- Open Access
Psychotropic Polypharmacy in a 5-Year-Old Boy with a SHANK3 Variant and Complex Mental Health Problems
Background: Dysfunction of the SHANK3 gene has been linked to several neuropsychiatric and neurodevelopmental disorders, such as attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder, and epilepsy. SHANK3 haploinsufficiency is the known etiology of Phelan–McDermid syndrome. Case presentation: This report presents a five-year-old boy in whom the c.2062G>C; p.Val688Leu variant was identified in a mosaic state in the SHANK3 gene (40% of heterozygous cells) and classified as a variant of uncertain significance (VUS). The patient was diagnosed with complex mental health problems, which, analogous to typical SHANK3 disruption, included ADHD, oppositional defiant disorder, developmental coordination disorder, Non-REM sleep arousal disorder, insomnia disorder, and avoidant/restrictive food intake disorder. Starting at the age of three years, his psychiatric treatment had included various medication trials over the course of two years. Ultimately, a substantial reduction in emotional outbursts, externalizing behaviors, and parental stress occurred following a multimodal treatment approach comprising psychotropic polypharmacy (PP), i.e., lisdexamfetamine, melatonin, and risperidone, along with behavioral therapy interventions, speech therapy, and occupational therapy. Under this PP, constipation was documented as the only adverse reaction. At the 15-month follow-up, improvements had been quite stable, despite risperidone medication being stopped about 19 weeks after initiation. Conclusions: As shown in this case report, even very young children with complex neuropsychiatric problems and SHANK3 variants might not be treated sufficiently by therapeutic interventions alone, but might require a combination of therapeutic and psychopharmacological interventions to achieve a substantial symptom reduction. However, PP must be approached with a high degree of caution and subjected to close monitoring in children with SHANK3 variants, who are susceptible to an elevated risk of adverse outcomes. Moreover, given the paucity of research in this population, it seems advisable to follow prevailing general guidelines in child and adolescent psychiatry.
Open AccessPsychotropic Polypharmacy in a 5-Year-Old Boy with a SHANK3 Variant and Complex Mental Health Problems
Background: Dysfunction of the SHANK3 gene has been linked to several neuropsychiatric and neurodevelopmental disorders, such as attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder, and epilepsy. SHANK3 haploinsufficiency is the known etiology of Phelan–McDermid syndrome. Case presentation: This report presents a five-year-old boy in whom the c.2062G>C; p.Val688Leu variant was identified in a mosaic state in the SHANK3 gene (40% of heterozygous cells) and classified as a variant of uncertain significance (VUS). The patient was diagnosed with complex mental health problems, which, analogous to typical SHANK3 disruption, included ADHD, oppositional defiant disorder, developmental coordination disorder, Non-REM sleep arousal disorder, insomnia disorder, and avoidant/restrictive food intake disorder. Starting at the age of three years, his psychiatric treatment had included various medication trials over the course of two years. Ultimately, a substantial reduction in emotional outbursts, externalizing behaviors, and parental stress occurred following a multimodal treatment approach comprising psychotropic polypharmacy (PP), i.e., lisdexamfetamine, melatonin, and risperidone, along with behavioral therapy interventions, speech therapy, and occupational therapy. Under this PP, constipation was documented as the only adverse reaction. At the 15-month follow-up, improvements had been quite stable, despite risperidone medication being stopped about 19 weeks after initiation. Conclusions: As shown in this case report, even very young children with complex neuropsychiatric problems and SHANK3 variants might not be treated sufficiently by therapeutic interventions alone, but might require a combination of therapeutic and psychopharmacological interventions to achieve a substantial symptom reduction. However, PP must be approached with a high degree of caution and subjected to close monitoring in children with SHANK3 variants, who are susceptible to an elevated risk of adverse outcomes. Moreover, given the paucity of research in this population, it seems advisable to follow prevailing general guidelines in child and adolescent psychiatry.
- 1 May 2026
- Published by Hogrefe Publishing Group in Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie
- Vol. 54 (3) , 139-150
Positive Child Relationship Behavior Toward Mothers in 3–7-Year-Old Children with Mental Disorders
Objective: A paucity of research exists on the subject of positive child relationship behavior toward parents, particularly in children with mental disorders. Method: We invited the mothers of children 3 to 7 years with mental disorders according to the ICD-10 to complete questionnaires on positive child relationship behavior, child behavior problems, maternal psychopathology, dysfunctional parenting, and maternal sense of competence. Results: 71 children (56 boys and 15 girls, mean age = 64.07 [ SD = 11.75] months with their mothers (mean age = 33.94 [ SD = 6.49] years) participated in this pilot study. Children with primarily internalizing disorders did not differ from the general population regarding the frequency of positive relationship-relevant behavior toward their mothers. Conversely, children with externalizing disorders and those with a residual diagnosis exhibited significantly lower frequencies of positive behavior toward their mothers. Dysfunctional parenting behavior and maternal psychopathology did not correlate with the frequency of children’s positive relationship behavior toward their mothers. However, maternal sense of competence correlated significantly positively with positive child relationship behavior. Conclusions: It is imperative to systematically assess positive child relationship behavior as perceived by their parents to obtain a more comprehensive perspective on the child.
- 1 May 2026
- Published by Hogrefe Publishing Group in Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie
- Vol. 54 (3) , 139-150
Positive Child Relationship Behavior Toward Mothers in 3–7-Year-Old Children with Mental Disorders
Objective: A paucity of research exists on the subject of positive child relationship behavior toward parents, particularly in children with mental disorders. Method: We invited the mothers of children 3 to 7 years with mental disorders according to the ICD-10 to complete questionnaires on positive child relationship behavior, child behavior problems, maternal psychopathology, dysfunctional parenting, and maternal sense of competence. Results: 71 children (56 boys and 15 girls, mean age = 64.07 [ SD = 11.75] months with their mothers (mean age = 33.94 [ SD = 6.49] years) participated in this pilot study. Children with primarily internalizing disorders did not differ from the general population regarding the frequency of positive relationship-relevant behavior toward their mothers. Conversely, children with externalizing disorders and those with a residual diagnosis exhibited significantly lower frequencies of positive behavior toward their mothers. Dysfunctional parenting behavior and maternal psychopathology did not correlate with the frequency of children’s positive relationship behavior toward their mothers. However, maternal sense of competence correlated significantly positively with positive child relationship behavior. Conclusions: It is imperative to systematically assess positive child relationship behavior as perceived by their parents to obtain a more comprehensive perspective on the child.
- Open Access
- 13 October 2025
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 19 (1) , 110
Off-label drug use in children and adolescents treated with antidepressants and antipsychotics: results from a prospective multicenter trial
Background/Objectives: Off-label psychopharmacologic medication use is widespread in child and adolescent psychiatry, but little is known about its associated factors. This study aimed to assess frequency and determinants of off-label use of antidepressants and antipsychotics in youths in daily clinical practice. Methods: In a prospective clinical study (‘TDM-VIGIL’) at 18 centers in three German-speaking countries, child psychiatric patients aged 4–18 years undergoing routine treatment with antidepressants and antipsychotics were systematically followed. Demographic, clinical and pharmacological data were collected in an online-based patient registry; off-label use was categorized by reasons, including age, indication or duration of treatment for each treatment episode. Examined correlates of off-label use included sex, treatment setting, diagnosis and illness severity. Results: About 67% of all antidepressant and antipsychotic treatment episodes in the 700 included patients (mean age = 14.6 years, girls = 67%) were off-label. For antidepressants, 55.2% were off-label (age = 51.1%, non-licensed indications = 37.4%, age + indication = 11.5%), for antipsychotics 81.7% were off-label (age = 29.4%, non-licensed indications = 33.2%, age + indication = 37.4%). Sex, age (< 12, ≥ 12 years) as well as illness severity were not associated with off-label use. In antidepressant treatment, ‘depression’ and ‘obsessive compulsive disorder’ diagnoses were associated with reduced and ‘suicidality at admission’ with increased off-label prescriptions. In antipsychotics, ‘schizophrenia diagnoses’ was linked to decreased, university hospital treatment to increased off-label use. Conclusions: The frequency of off-label use of antidepressants and even more of antipsychotics in youths treated at specialized child psychiatric centers is high. As the clinical efficacy and safety of off-label antidepressant and antipsychotic use in youth is under-researched, our results call for further pharmacovigilance studies and strategies to improve drug safety.
- 13 October 2025
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 19 (1) , 110
Open AccessOff-label drug use in children and adolescents treated with antidepressants and antipsychotics: results from a prospective multicenter trial
Background/Objectives: Off-label psychopharmacologic medication use is widespread in child and adolescent psychiatry, but little is known about its associated factors. This study aimed to assess frequency and determinants of off-label use of antidepressants and antipsychotics in youths in daily clinical practice. Methods: In a prospective clinical study (‘TDM-VIGIL’) at 18 centers in three German-speaking countries, child psychiatric patients aged 4–18 years undergoing routine treatment with antidepressants and antipsychotics were systematically followed. Demographic, clinical and pharmacological data were collected in an online-based patient registry; off-label use was categorized by reasons, including age, indication or duration of treatment for each treatment episode. Examined correlates of off-label use included sex, treatment setting, diagnosis and illness severity. Results: About 67% of all antidepressant and antipsychotic treatment episodes in the 700 included patients (mean age = 14.6 years, girls = 67%) were off-label. For antidepressants, 55.2% were off-label (age = 51.1%, non-licensed indications = 37.4%, age + indication = 11.5%), for antipsychotics 81.7% were off-label (age = 29.4%, non-licensed indications = 33.2%, age + indication = 37.4%). Sex, age (< 12, ≥ 12 years) as well as illness severity were not associated with off-label use. In antidepressant treatment, ‘depression’ and ‘obsessive compulsive disorder’ diagnoses were associated with reduced and ‘suicidality at admission’ with increased off-label prescriptions. In antipsychotics, ‘schizophrenia diagnoses’ was linked to decreased, university hospital treatment to increased off-label use. Conclusions: The frequency of off-label use of antidepressants and even more of antipsychotics in youths treated at specialized child psychiatric centers is high. As the clinical efficacy and safety of off-label antidepressant and antipsychotic use in youth is under-researched, our results call for further pharmacovigilance studies and strategies to improve drug safety.
- Open Access
- 30 July 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (8) , 983
Sex-Specific Differences in Antidepressant and Antipsychotic Treatment Outcomes and Serum Levels in Children and Adolescents
Introduction: Sex-specific differences in psychopharmacological treatment have gained increasing attention in adults, with studies showing that women often have higher serum concentrations of psychotropic drugs due to biological differences. However, despite recognition of these differences in adults, reference ranges for therapeutic drug monitoring (TDM) in general, but even more sex-specific therapeutic windows for psychotropic drugs, are lacking in children and adolescents, who may metabolize and respond to medications differently. Aim: The study aimed to investigate sex-specific differences in antidepressant (AD) and antipsychotic (AP) -treatment outcomes, and pharmacokinetics in childhood/adolescence. In particular, we examined differences in AD and AP serum levels and clinical effects, including adverse drug effects (ADEs) and therapeutic effectiveness. Methods: This study is part of the multicenter “TDM-VIGIL” pharmacovigilance project, which prospectively followed patients aged 6–18 years treated with AD and AP across 18 child psychiatric centers in German-speaking countries from 2014 to 2018. Clinical data, including drug concentrations (AD: fluoxetine, mirtazapine, (es)citalopram, sertraline; AP: aripiprazole, quetiapine, olanzapine, risperidone), were collected using an internet-based registry, and treatment outcomes and ADEs were assessed during routine visits. Statistical analyses were performed to examine sex differences in pharmacokinetics and clinical responses, adjusting for age, weight, and other confounders. Results: A total of 705 patients (66.5% girls, 24.7% p = 0.04), as well as with moderate treatment response (p = 0.02) compared to no treatment response. Discussion: Our findings suggest that sex may not affect serum levels of investigated AD and AP in children/adolescents. However, treatment outcome of fluoxetine was associated with sex, with higher probability for a better outcome in female patients diagnosed with mood (affective) disorders.
- 30 July 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (8) , 983
Open AccessSex-Specific Differences in Antidepressant and Antipsychotic Treatment Outcomes and Serum Levels in Children and Adolescents
Introduction: Sex-specific differences in psychopharmacological treatment have gained increasing attention in adults, with studies showing that women often have higher serum concentrations of psychotropic drugs due to biological differences. However, despite recognition of these differences in adults, reference ranges for therapeutic drug monitoring (TDM) in general, but even more sex-specific therapeutic windows for psychotropic drugs, are lacking in children and adolescents, who may metabolize and respond to medications differently. Aim: The study aimed to investigate sex-specific differences in antidepressant (AD) and antipsychotic (AP) -treatment outcomes, and pharmacokinetics in childhood/adolescence. In particular, we examined differences in AD and AP serum levels and clinical effects, including adverse drug effects (ADEs) and therapeutic effectiveness. Methods: This study is part of the multicenter “TDM-VIGIL” pharmacovigilance project, which prospectively followed patients aged 6–18 years treated with AD and AP across 18 child psychiatric centers in German-speaking countries from 2014 to 2018. Clinical data, including drug concentrations (AD: fluoxetine, mirtazapine, (es)citalopram, sertraline; AP: aripiprazole, quetiapine, olanzapine, risperidone), were collected using an internet-based registry, and treatment outcomes and ADEs were assessed during routine visits. Statistical analyses were performed to examine sex differences in pharmacokinetics and clinical responses, adjusting for age, weight, and other confounders. Results: A total of 705 patients (66.5% girls, 24.7% p = 0.04), as well as with moderate treatment response (p = 0.02) compared to no treatment response. Discussion: Our findings suggest that sex may not affect serum levels of investigated AD and AP in children/adolescents. However, treatment outcome of fluoxetine was associated with sex, with higher probability for a better outcome in female patients diagnosed with mood (affective) disorders.
- 1 May 2025
- Published by Hogrefe Publishing Group in Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie
- Vol. 53 (3) , 166-172
Autoimmune Psychosis as a Differential Diagnosis of Primary Schizophreniform Psychosis in Children and Adolescents
Objective: Autoimmune psychosis (AP), defined as an isolated schizophreniform psychosis with no or only minimal neurological abnormalities stemming from autoantibody-associated cerebral processes, is a very rare and potentially underdiagnosed disorder in children and adolescents. Methods: This article reports the case of a 13-year-old boy who became acutely ill with a psychotic disorder following a respiratory infection. We describe the diagnosis and course of treatment in detail. Results: Following an extensive interdisciplinary workup, a probable glutamic acid decarboxylase (GAD)-associated AP was diagnosed that ultimately remitted completely with treatment. Conclusions: Autoimmune psychoses remain a relatively uncharted territory for the specialty of child and adolescent psychiatry. Good interdisciplinary cooperation is essential for patients with somewhat atypical psychotic symptoms, both in terms of diagnosis and treatment.
- 1 May 2025
- Published by Hogrefe Publishing Group in Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie
- Vol. 53 (3) , 166-172
Autoimmune Psychosis as a Differential Diagnosis of Primary Schizophreniform Psychosis in Children and Adolescents
Objective: Autoimmune psychosis (AP), defined as an isolated schizophreniform psychosis with no or only minimal neurological abnormalities stemming from autoantibody-associated cerebral processes, is a very rare and potentially underdiagnosed disorder in children and adolescents. Methods: This article reports the case of a 13-year-old boy who became acutely ill with a psychotic disorder following a respiratory infection. We describe the diagnosis and course of treatment in detail. Results: Following an extensive interdisciplinary workup, a probable glutamic acid decarboxylase (GAD)-associated AP was diagnosed that ultimately remitted completely with treatment. Conclusions: Autoimmune psychoses remain a relatively uncharted territory for the specialty of child and adolescent psychiatry. Good interdisciplinary cooperation is essential for patients with somewhat atypical psychotic symptoms, both in terms of diagnosis and treatment.
- 28 January 2025
- Published by Georg Thieme Verlag KG in Das Gesundheitswesen
- Vol. 87 (07) , 497-500
Gesetzliche Vorgaben zur Aufklärung und deren Einfluss auf die Patientenzufriedenheit
Zusammenfassung: Das Patientenrechtegesetz definiert unter anderem ärztliche Pflichten im Zusammenhang mit der Aufklärung. Bis dato wurde in Deutschland nicht untersucht, inwiefern diese gesetzlichen Vorgaben auch die Zufriedenheit mit der Aufklärung beeinflussen, Dieser unter dem Gesichtspunkt des Qualitätsmanagements wichtigen Frage widmet sich diese Studie.Anonymisierte Patientenbefragung zur Zufriedenheit mit der Aufklärung, die mittels eines validierten 10 Item-Fragebogens erfasst wurde.189 Aufklärungsgespräche (n=105 weibliche, n=84 männliche Patienten) gingen in die Auswertung ein. 87,8% (n=166) der Patienten befanden sich in stationärer Behandlung, 12,2% (n=23) wurden ambulant behandelt. Die Patienten waren im Mittel 53,2 Jahre alt (Standardabweichung: 20,3 Jahre, Spannbreite: 15 bis 97 Jahre) und verteilten sich über folgende Behandlungsbereiche: Anästhesie: n=68; Chirurgie: n=60; Innere Medizin: n=56; Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie: n=5 Patienten. Es ergab sich insgesamt eine hohe Zufriedenheit mit der Aufklärung, die sich zwischen den Geschlechtern nicht signifikant unterschied. Allerdings waren Patienten zufriedener, wenn sie von Ärzten mit Deutsch als Muttersprache (p=0,005; d=0,214) bzw. von Fachärzten (p<0,001; d=0,288) aufgeklärt wurden. Die Dauer des Aufklärungsgesprächs korrelierte signifikant positiv mit der Zufriedenheit (p=0,002, r=0,211). Es konnte außerdem gezeigt werden, dass dem Weiterbildungsstand des Arztes (Facharzt: Ja/Nein) die größte Bedeutung zukommt (adjusted Odds Ratio: 4,48).Die Vorgaben des Patientenrechtegesetzes bzgl. Verständlichkeit und Ausführlichkeit der Aufklärung sowie Kompetenz des aufklärenden Arztes tragen nachweislich zur Patientenzufriedenheit bei. Daher ist immer auf eine ausreichende fachliche Kompetenz zu achten. Bei aufklärenden Ärzten, deren Muttersprache nicht Deutsch ist, sollte der Einsatz von Übersetzungsprogrammen, Informationen in bildlicher Form oder von (zusätzlichen) Video-Aufklärungen erwogen werden, um eine etwaige Sprachbarriere zu minimieren. Darüber hinaus sollte für eine möglichst hohe Zufriedenheit die Dauer des Aufklärungsgespräches möglichst gut an die individuellen Patientenbedürfnisse angepasst werden. Dazu empfiehlt es sich, die Patienten vorab zu fragen, wie ausführlich sie sich die Aufklärung wünschen.
- 28 January 2025
- Published by Georg Thieme Verlag KG in Das Gesundheitswesen
- Vol. 87 (07) , 497-500
Gesetzliche Vorgaben zur Aufklärung und deren Einfluss auf die Patientenzufriedenheit
Zusammenfassung: Das Patientenrechtegesetz definiert unter anderem ärztliche Pflichten im Zusammenhang mit der Aufklärung. Bis dato wurde in Deutschland nicht untersucht, inwiefern diese gesetzlichen Vorgaben auch die Zufriedenheit mit der Aufklärung beeinflussen, Dieser unter dem Gesichtspunkt des Qualitätsmanagements wichtigen Frage widmet sich diese Studie.Anonymisierte Patientenbefragung zur Zufriedenheit mit der Aufklärung, die mittels eines validierten 10 Item-Fragebogens erfasst wurde.189 Aufklärungsgespräche (n=105 weibliche, n=84 männliche Patienten) gingen in die Auswertung ein. 87,8% (n=166) der Patienten befanden sich in stationärer Behandlung, 12,2% (n=23) wurden ambulant behandelt. Die Patienten waren im Mittel 53,2 Jahre alt (Standardabweichung: 20,3 Jahre, Spannbreite: 15 bis 97 Jahre) und verteilten sich über folgende Behandlungsbereiche: Anästhesie: n=68; Chirurgie: n=60; Innere Medizin: n=56; Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie: n=5 Patienten. Es ergab sich insgesamt eine hohe Zufriedenheit mit der Aufklärung, die sich zwischen den Geschlechtern nicht signifikant unterschied. Allerdings waren Patienten zufriedener, wenn sie von Ärzten mit Deutsch als Muttersprache (p=0,005; d=0,214) bzw. von Fachärzten (p<0,001; d=0,288) aufgeklärt wurden. Die Dauer des Aufklärungsgesprächs korrelierte signifikant positiv mit der Zufriedenheit (p=0,002, r=0,211). Es konnte außerdem gezeigt werden, dass dem Weiterbildungsstand des Arztes (Facharzt: Ja/Nein) die größte Bedeutung zukommt (adjusted Odds Ratio: 4,48).Die Vorgaben des Patientenrechtegesetzes bzgl. Verständlichkeit und Ausführlichkeit der Aufklärung sowie Kompetenz des aufklärenden Arztes tragen nachweislich zur Patientenzufriedenheit bei. Daher ist immer auf eine ausreichende fachliche Kompetenz zu achten. Bei aufklärenden Ärzten, deren Muttersprache nicht Deutsch ist, sollte der Einsatz von Übersetzungsprogrammen, Informationen in bildlicher Form oder von (zusätzlichen) Video-Aufklärungen erwogen werden, um eine etwaige Sprachbarriere zu minimieren. Darüber hinaus sollte für eine möglichst hohe Zufriedenheit die Dauer des Aufklärungsgespräches möglichst gut an die individuellen Patientenbedürfnisse angepasst werden. Dazu empfiehlt es sich, die Patienten vorab zu fragen, wie ausführlich sie sich die Aufklärung wünschen.
- Open Access
- 25 August 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (9) , 2202
Therapeutic Drug Monitoring in Children and Adolescents: Findings on Fluoxetine from the TDM-VIGIL Trial
Fluoxetine is the recommended first-line antidepressant in many therapeutic guidelines for children and adolescents. However, little is known about the relationships between drug dose and serum level as well as the therapeutic serum reference range in this age group. Within a large naturalistic observational prospective multicenter clinical trial (“TDM-VIGIL”), a transdiagnostic sample of children and adolescents (n = 138; mean age, 15; range, 7–18 years; 24.6% males) was treated with fluoxetine (10–40 mg/day). Analyses of both the last timepoint and all timepoints (n = 292 observations), utilizing (multiple) linear regressions, linear mixed-effect models, and cumulative link (mixed) models, were used to test the associations between dose, serum concentration, outcome, and potential predictors. The receiver operating curve and first to third interquartile methods, respectively, were used to examine concentration cutoff and reference values for responders. A strong positive relationship was found between dose and serum concentration of fluoxetine and its metabolite. Higher body weight was associated with lower serum concentrations, and female sex was associated with lower therapeutic response. The preliminary reference ranges for the active moiety (fluoxetine+norfluoxetine) were 208–328 ng/mL (transdiagnostically) and 201.5–306 ng/mL (depression). Most patients showed marked (45.6%) or minimal (43.5%) improvements and reported no adverse effects (64.9%). This study demonstrated a clear linear dose–serum level relationship for fluoxetine in youth, with the identified reference range being within that established for adults.
- 25 August 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (9) , 2202
Open AccessTherapeutic Drug Monitoring in Children and Adolescents: Findings on Fluoxetine from the TDM-VIGIL Trial
Fluoxetine is the recommended first-line antidepressant in many therapeutic guidelines for children and adolescents. However, little is known about the relationships between drug dose and serum level as well as the therapeutic serum reference range in this age group. Within a large naturalistic observational prospective multicenter clinical trial (“TDM-VIGIL”), a transdiagnostic sample of children and adolescents (n = 138; mean age, 15; range, 7–18 years; 24.6% males) was treated with fluoxetine (10–40 mg/day). Analyses of both the last timepoint and all timepoints (n = 292 observations), utilizing (multiple) linear regressions, linear mixed-effect models, and cumulative link (mixed) models, were used to test the associations between dose, serum concentration, outcome, and potential predictors. The receiver operating curve and first to third interquartile methods, respectively, were used to examine concentration cutoff and reference values for responders. A strong positive relationship was found between dose and serum concentration of fluoxetine and its metabolite. Higher body weight was associated with lower serum concentrations, and female sex was associated with lower therapeutic response. The preliminary reference ranges for the active moiety (fluoxetine+norfluoxetine) were 208–328 ng/mL (transdiagnostically) and 201.5–306 ng/mL (depression). Most patients showed marked (45.6%) or minimal (43.5%) improvements and reported no adverse effects (64.9%). This study demonstrated a clear linear dose–serum level relationship for fluoxetine in youth, with the identified reference range being within that established for adults.
- Open Access
- 17 November 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (22) , 12064
Psychiatric Comorbidities in 1p36 Deletion Syndrome and Their Treatment—A Case Report
1p36 deletion syndrome represents the most common terminal deletion observed in humans. Major clinical findings comprise developmental delay/intellectual disability, poor or absent expressive language, congenital central muscular hypotonia, brain anomalies, brachydactyly/camptodactyly, short feet, and characteristic facial features like straight eyebrows, deep-set eyes, and midface hypoplasia. So far, there is very limited knowledge about comorbid psychiatric disorders and their effective treatment in this special population. To fill this gap, this case report presents an initially four-year-old girl with 1p36.33–1p36.32 deletion, moderate intellectual disability, insomnia, oppositional-defiant disorder and attention deficit/hyperactivity disorder covering a period of time of about 1.5 years comprising initial psychological/psychiatric assessment, subsequent day clinic/outpatient treatment (amongst others including off-label use of melatonin and methylphenidate as well as parent-child interaction therapy) and follow-up assessment. Follow-up results indicated good efficacy of melatonin and methylphenidate medication without any adverse effects. Multidisciplinarity in diagnosis and treatment are mandatory to meet needs of patients with complex genetic disorders like 1p36 deletion syndrome. Off-label use of melatonin (for insomnia) and methylphenidate (for attention deficit/hyperactivity disorder) should be considered in young children with 1p36 deletion syndrome if behavioral interventions are not sufficient.
- 17 November 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (22) , 12064
Open AccessPsychiatric Comorbidities in 1p36 Deletion Syndrome and Their Treatment—A Case Report
1p36 deletion syndrome represents the most common terminal deletion observed in humans. Major clinical findings comprise developmental delay/intellectual disability, poor or absent expressive language, congenital central muscular hypotonia, brain anomalies, brachydactyly/camptodactyly, short feet, and characteristic facial features like straight eyebrows, deep-set eyes, and midface hypoplasia. So far, there is very limited knowledge about comorbid psychiatric disorders and their effective treatment in this special population. To fill this gap, this case report presents an initially four-year-old girl with 1p36.33–1p36.32 deletion, moderate intellectual disability, insomnia, oppositional-defiant disorder and attention deficit/hyperactivity disorder covering a period of time of about 1.5 years comprising initial psychological/psychiatric assessment, subsequent day clinic/outpatient treatment (amongst others including off-label use of melatonin and methylphenidate as well as parent-child interaction therapy) and follow-up assessment. Follow-up results indicated good efficacy of melatonin and methylphenidate medication without any adverse effects. Multidisciplinarity in diagnosis and treatment are mandatory to meet needs of patients with complex genetic disorders like 1p36 deletion syndrome. Off-label use of melatonin (for insomnia) and methylphenidate (for attention deficit/hyperactivity disorder) should be considered in young children with 1p36 deletion syndrome if behavioral interventions are not sufficient.